Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888

Translational Oncology

Volumn 7, Issue 3, 2014, Pages 439-445

  Tuli, Richard ^a   Surmak, Andrew J ^b   Reyes, Juvenal ^b   Armour, Michael ^b   Hacker Prietz, Amy ^b   Wong, John ^b   DeWeese, Theodore L ^b   Herman, Joseph M ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85100435774     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.04.003     Document Type: Article

References (35)

1. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2013. CA Cancer J Clin 63 (2013), 11–30.
2. Ben-Josef, E., Lawrence, T.S., Chemoradiotherapy for unresectable pancreatic cancer. Int J Clin Oncol 13 (2008), 121–126.
3. Goodman, K.A., Hajj, C., Role of radiation therapy in the management of pancreatic cancer. J Surg Oncol 107 (2013), 86–96.
4. Iacobuzio-Donahue, C.A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C.M., Vilardell, F., Wang, Z., Keller, J.W., Banerjee, P., et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27 (2009), 1806–1813.
5. Burris, H.A. III, Moore, M.J., Andersen, J., Green, M.R., Rothenberg, M.L., Modiano, M.R., Cripps, M.C., Portenoy, R.K., Storniolo, A.M., Tarassoff, P., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997), 2403–2413.
6. Lawrence, T.S., Chang, E.Y., Hahn, T.M., Hertel, L.W., Shewach, D.S., Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. Int J Radiat Oncol Biol Phys 34 (1996), 867–872.
7. McGinn, C.J., Zalupski, M.M., Shureiqi, I., Robertson, J.M., Eckhauser, F.E., Smith, D.C., Brown, D., Hejna, G., Strawderman, M., Normolle, D., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19 (2001), 4202–4208.
8. Ben-Josef, E., Schipper, M., Francis, I.R., Hadley, S., Ten-Haken, R., Lawrence, T., Normolle, D., Simeone, D.M., Sonnenday, C., Abrams, R., et al. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 84 (2012), 1166–1171.
9. Galande, S., Kohwi-Shigematsu, T., Poly(ADP-ribose) polymerase and Ku autoantigen form a complex and synergistically bind to matrix attachment sequences. J Biol Chem 274 (1999), 20521–20528.
10. Memisoglu, A., Samson, L., Base excision repair in yeast and mammals. Mutat Res 451 (2000), 39–51.
11. Ruscetti, T., Lehnert, B.E., Halbrook, J., Le Trong, H., Hoekstra, M.F., Chen, D.J., Peterson, S.R., Stimulation of the DNA-dependent protein kinase by poly(ADP-ribose) polymerase. J Biol Chem 273 (1998), 14461–14467.
12. Ame, J.C., Spenlehauer, C., de Murcia, G., The PARP superfamily. Bioessays 26 (2004), 882–893.
13. Shiobara, M., Miyazaki, M., Ito, H., Togawa, A., Nakajima, N., Nomura, F., Morinaga, N., Noda, M., Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 16 (2001), 338–344.
14. Dungey, F.A., Loser, D.A., Chalmers, A.J., Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 72 (2008), 1188–1197.
15. Efimova, E.V., Mauceri, H.J., Golden, D.W., Labay, E., Bindokas, V.P., Darga, T.E., Chakraborty, C., Barreto-Andrade, J.C., Crawley, C., Sutton, H.G., et al. Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res 70 (2010), 6277–6282.
16. Rouleau, M., Patel, A., Hendzel, M.J., Kaufmann, S.H., Poirier, GG PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10 (2010), 293–301.
17. Donawho, C.K., Luo, Y., Luo, Y., Penning, T.D., Bauch, J.L., Bouska, J.J., Bontcheva-Diaz, V.D., Cox, B.F., DeWeese, T.L., Dillehay, L.E., et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13 (2007), 2728–2737.
18. Tuli, R., Armour, M., Surmak, A., Reyes, J., Iordachita, I., Patterson, M., Wong, J., Accuracy of off-line bioluminescence imaging to localize targets in preclinical radiation research. Radiat Res 179 (2013), 416–421.
19. Tuli, R., Surmak, A., Reyes, J., Hacker-Prietz, A., Armour, M., Leubner, A., Blackford, A., Tryggestad, E., Jaffee, E.M., Wong, J., et al. Development of a novel preclinical pancreatic cancer research model: bioluminescence image-guided focal irradiation and tumor monitoring of orthotopic xenografts. Transl Oncol 5 (2013), 77–84.
20. Black, P.C., Shetty, A., Brown, G.A., Esparza-Coss, E., Metwalli, A.R., Agarwal, P.K., McConkey, D.J., Hazle, J.D., Dinney, C.P., Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis. BJU Int 106 (2010), 1799–1804.
21. Horton, J.K., Stefanick, D.F., Wilson, S.H., Involvement of poly(ADP-ribose) polymerase activity in regulating Chk1-dependent apoptotic cell death. DNA Repair (Amst) 4 (2005), 1111–1120.
22. Bromfield, G.P., Meng, A., Warde, P., Bristow, R.G., Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer Prostatic Dis 6 (2003), 73–85.
23. Wang, Z.Q., Stingl, L., Morrison, C., Jantsch, M., Los, M., Schulze-Osthoff, K., Wagner, E.F., PARP is important for genomic stability but dispensable in apoptosis. Genes Dev 11 (1997), 2347–2358.
24. Liu, S.K., Coackley, C., Krause, M., Jalali, F., Chan, N., Bristow, R.G., A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol 88 (2008), 258–268.
25. Metzger, M.J., Stoddard, B.L., Monnat, R.J. Jr., PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks. DNA Repair (Amst) 12 (2013), 529–534.
26. Murai, J., Huang, S.N., Das, B.B., Renaud, A., Zhang, Y., Doroshow, J.H., Ji, J., Takeda, S., Pommier, Y., Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72 (2012), 5588–5599.
27. Jacob, D.A., Bahra, M., Langrehr, J.M., Boas-Knoop, S., Stefaniak, R., Davis, J., Schumacher, G., Lippert, S., Neumann, U.P., Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. J Gastroenterol Hepatol 22 (2007), 738–748.
28. Mini, E., Nobili, S., Caciagli, B., Landini, I., Mazzei, T., Cellular pharmacology of gemcitabine. Ann Oncol 17:Suppl. 5 (2006), v7–v12.
29. Loehrer, P.J. Sr., Feng, Y., Cardenes, H., Wagner, L., Brell, J.M., Cella, D., Flynn, P., Ramanathan, R.K., Crane, C.H., Alberts, S.R., et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29 (2011), 4105–4112.
30. Gartner, E.M., Burger, A.M., Lorusso, P.M., Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future. Cancer J 16 (2010), 83–90.
31. Cass, I., Baldwin, R.L., Varkey, T., Moslehi, R., Narod, S.A., Karlan, B.Y., Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97 (2003), 2187–2195.
32. Fogelman, D.R., Wolff, R.A., Kopetz, S., Javle, M., Bradley, C., Mok, I., Cabanillas, F., Abbruzzese, J.L., Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res 31 (2011), 1417–1420.
33. Hennessy, B.T., Timms, K.M., Carey, M.S., Gutin, A., Meyer, L.A., Flake, D.D. II, Abkevich, V., Potter, J., Pruss, D., Glenn, P., et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 28 (2010), 3570–3576.
34. Dedes, K.J., Wilkerson, P.M., Wetterskog, D., Weigelt, B., Ashworth, A., Reis-Filho, J.S., Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 10 (2011), 1192–1199.
35. Murphy, K.M., Brune, K.A., Griffin, C., Sollenberger, J.E., Petersen, G.M., Bansal, R., Hruban, R.H., Kern, S.E., Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 62 (2002), 3789–3793.